Aquaculture trial: Cabanin® CSD in Nile tilapia — growth, FCR & stress resilience

Trial name 
Potential Effects of Dietary Cabanin® CSD on Growth Performance and Biochemical and Antioxidant Responses of Nile Tilapia (Oreochromis niloticus)  

Year: 2024  

Country: Vietnam (Nong Lam University, Ho Chi Minh City)  

This university trial was carried out at the Experimental Farm of Nong Lam University in Ho Chi Minh City, Vietnam, using Nile tilapia fingerlings from a local farm. The objective was to evaluate how Cabanin® CSD affects growth performance and stress resistance in tilapia. Fish were fed one of four diets with different vitamin E/C levels and Cabanin® inclusion during a 10-week feeding period, followed by a 168-hour ammonia challenge test (TAN 60 mg/L) to assess robustness under stress

Results

• Higher final body weight: up to 109.91 g with Cabanin® vs 97.49 g in control (p < 0.05).
• Improved feed conversion: FCR 1.07 with Cabanin® vs 1.34 in control (p < 0.05).
• Stronger antioxidant profile: higher SOD and lower TBARS in blood serum with Cabanin® (p < 0.05).
• Lower lipid oxidation in fillets: TBARS were lower in Cabanin® groups at day 1 and day 7 of refrigerated storage (p < 0.05).
• Ammonia challenge: Cabanin® groups showed higher survival after 168 hours compared to controls (p < 0.05).

Conclusion

Cabanin® CSD at 200–400 mg/kg feed supported growth, feed utilization, and antioxidant capacity, and improved robustness under ammonia stress. The authors conclude 200 mg/kg as the most suitable level for tilapia aquafeed.